Study on the benefit of quercetin intake in diabetic patients treated with antidiabetic tablets. A two-arm, prospective randomized control clinical trial (interventional vs observation group) in primary health care.

niversity of Crete0 个研究点目标入组 100 人开始时间: 2023年1月17日最近更新: 2024年1月8日

适应症

试验速览

暂无简介。

•Eligible participants will be type II diabetes patients treated with antidiabetic tablets, with an age over 50 years who belong to the registered population of responsibility of the 4th Local Health Unit (TOMY) of Heraklion.

•Highly vulnerable individuals will be excluded, following the relevant legal and ethical rules. The above cases are also excluded:
•1. Gestational diabetes (breastfeeding/pregnancy),
•2. Maturity-onset diabetes of the young (MODY),
•3. Pancreatogenic diabetes (T3CDM),
•4. Heart, liver or kidney disease,
•5. Serious psychiatric illness or addiction,
•6. Patients with comorbidities such as cancer, AIDS, neoplastic diseases,
•7. Organ transplant patients, patients under immunosuppressive therapy,
•8. Patients who have recently suffered a cardiovascular event, within three months before the start of the study,
•9. Patients using other antioxidant supplementations,
•10. Patients with a requirement for long-term use of aspirin, other than low dosage for protection against cardiovascular events, or NSAIDs,
•11. Patients participating in another interventional clinical study,
•12. Patients with planned surgery or other interventional procedure requiring systemic anesthesia during the study.

发起方

niversity of Crete